Living Cell Technologies Ltd. (LVCLY: OTCQX International) | NTCELL® Continues to Reverse the Progression of Parkinson’s Disease – One Year after Implant

NTCELL® Continues to Reverse the Progression of Parkinson’s Disease – One Year after Implant

Jan 26, 2016

OTC Disclosure News Service

Over a year after treatment all four patients who took part in Living
Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL®
for Parkinson’s disease remain well, and at 58 weeks post-implant there
are no safety concerns.

In all four patients NTCELL treatment has stopped the progression of
Parkinson’s disease as measured by globally accepted and validated
neurological rating scales.

After 58 weeks there is a clinically and statistically significant
improvement in all the patients’ neurological score from their
pre-implant baseline. A graph of this is viewable on the ASX website here.

Parkinson’s disease progression is measured by a neurological rating
scale, Unified Parkinson’s Disease Rating Scale (UPDRS). The UPDRS score
increases by approximately 4 to 5 points each year as Parkinson’s
disease progresses.

NTCELL’s ability to decrease UPDRS by an average of 16 points after 58
weeks is clinically significant, representing a 3 to 4 year reversal of
neurological deterioration. In the first patient the improvement is
maintained at 74 weeks after NTCELL implant.

Dr Ken Taylor, chief executive, says the sustained improvement of the
patients is pleasing, particularly as no other treatment has been able
to maintain long term reversal of the effects of Parkinson’s disease.

“We are delighted with the continued positive outcome of the study. It
certainly adds anticipation and motivation to our authorised Phase IIb
study, which we plan to initiate on 24 February.”

The planned Phase IIb study aims to confirm the most effective dose of
NTCELL, define any placebo component of the response and further
identify the initial target Parkinson’s disease patient sub group.

“Our goal is to obtain provisional consent and launch NTCELL as the
first disease modifying treatment for Parkinson’s disease in 2017,” says
Dr Taylor.

For further information: www.lctglobal.com

Copyright © 2016 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/LVCLY/news?id=123930

Leave a Reply

WP2Social Auto Publish Powered By : XYZScripts.com
Bunk Beds